down arrow

Revvity, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US7140461093
USD
102.55
-0.71 (-0.69%)

Dec 04

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

99.62103.46

52 Week

81.36128.28
Valuation
Technical
Day's Volume

CASH

301.25 k

Shareholding (Mar 2025)

FII

24.63%

Held by 281 FIIs

DII

17.95%

Held by 73 DIIs

Promoter

0.01%

How big is Revvity, Inc.?

22-Jun-2025

As of Jun 18, Revvity, Inc. has a market capitalization of 11,098.61 million, with net sales of 2,769.86 million and a net profit of 296.05 million over the latest four quarters. The company reported shareholder's funds of 7,666.87 million and total assets of 12,392.48 million as of Dec 24.

Market Cap: As of Jun 18, Revvity, Inc. has a market capitalization of 11,098.61 million, categorizing it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Revvity, Inc. reported net sales of 2,769.86 million and a net profit of 296.05 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 7,666.87 million and total assets of 12,392.48 million.

Read More

What does Revvity, Inc. do?

22-Jun-2025

Revvity, Inc. is a mid-cap provider of products and solutions in the Pharmaceuticals & Biotechnology industry, with recent net sales of $665 million and a net profit of $42 million. Key metrics include a P/E ratio of 33.00 and a market cap of approximately $11.1 billion.

Overview:<BR>Revvity, Inc. is a provider of products, services, and solutions in the Pharmaceuticals & Biotechnology industry, operating within the mid-cap market.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 665 Million (Quarterly Results - Mar 2025)<BR>Most recent Net Profit: 42 Million (Quarterly Results - Mar 2025)<BR>Market-cap: USD 11,098.61 Million (Mid Cap)<BR><BR>Key Metrics:<BR>P/E: 33.00<BR>Dividend Yield: 0.31%<BR>Debt Equity: 0.27<BR>Return on Equity: 4.30%<BR>Price to Book: 1.45<BR><BR>Contact Details:<BR>Address: 155 Federal St Ste 700, BOSTON MA: 02110-1727<BR>Tel: 1 781 6635776<BR>Website: http://www.perkinelmer.com/

Read More

Who are in the management team of Revvity, Inc.?

22-Jun-2025

As of March 2022, the management team of Revvity, Inc. includes Mr. Alexandros Michas (Independent Non-Executive Chairman), Mr. Prahlad Singh (President and CEO), and several Independent Directors: Dr. Peter Barrett, Mr. Samuel Chapin, Dr. Sylvie Gregoire, and Mr. Michel Vounatsos. This team combines executive leadership with independent oversight for the company's governance and strategy.

As of March 2022, the management team of Revvity, Inc. includes the following individuals:<BR><BR>- Mr. Alexandros Michas, who serves as the Independent Non-Executive Chairman of the Board.<BR>- Mr. Prahlad Singh, who is the President, Chief Executive Officer, and Director.<BR>- Dr. Peter Barrett, who is an Independent Director.<BR>- Mr. Samuel Chapin, who is also an Independent Director.<BR>- Dr. Sylvie Gregoire, serving as an Independent Director.<BR>- Mr. Michel Vounatsos, who is another Independent Director.<BR><BR>This team comprises a mix of executive leadership and independent directors, contributing to the governance and strategic direction of the company.

Read More

Is Revvity, Inc. technically bullish or bearish?

07-Oct-2025

As of October 3, 2025, Revvity, Inc. shows a mildly bearish trend with mixed technical signals, having outperformed the S&P 500 recently but underperformed year-to-date.

As of 3 October 2025, the technical trend for Revvity, Inc. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD remains bearish. The Bollinger Bands indicate a mildly bullish stance on the weekly chart but are mildly bearish on the monthly. Daily moving averages are mildly bearish, and the KST shows bearish signals for both weekly and monthly periods. Dow Theory indicates no trend on the weekly and mildly bearish on the monthly. <BR><BR>In terms of performance, Revvity has outperformed the S&P 500 over the past week and month, with returns of 10.90% and 7.78% respectively, but has significantly underperformed over longer periods, including a -16.33% return year-to-date compared to the S&P 500's 14.18%. Overall, the current technical stance is mildly bearish, with mixed signals across different time frames.

Read More

Is Revvity, Inc. overvalued or undervalued?

05-Nov-2025

As of October 31, 2025, Revvity, Inc. is considered very expensive and overvalued with a P/E ratio of 33 and an EV to EBITDA of 15.29, significantly underperforming the S&P 500 with a year-to-date return of -17.85%.

As of 31 October 2025, the valuation grade for Revvity, Inc. has moved from attractive to very expensive, indicating a shift towards overvaluation. The company appears to be overvalued, with a P/E ratio of 33, an EV to EBITDA of 15.29, and a PEG ratio of 3.05, which are all higher than the industry average. In comparison, The Cooper Cos., Inc. has a P/E of 34.28 and an EV to EBITDA of 14.70, while Align Technology, Inc. shows a more favorable P/E of 20.46 and an EV to EBITDA of 11.41.<BR><BR>Furthermore, Revvity's stock has underperformed relative to the S&P 500, with a year-to-date return of -17.85% compared to the S&P 500's 16.30%, and a three-year return of -28.07% versus the S&P 500's 76.66%. This significant underperformance reinforces the notion that the stock is overvalued in its current state.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Poor Management Efficiency with a low ROCE of 10.24%

  • The company has been able to generate a Return on Capital Employed (avg) of 10.24% signifying low profitability per unit of total capital (equity and debt)
2

Poor long term growth as Net Sales has grown by an annual rate of -1.23% and Operating profit at -2.67% over the last 5 years

 
3

Flat results in Jun 25

4

With ROCE of 4.39%, it has a very expensive valuation with a 1.33 Enterprise value to Capital Employed

5

Consistent Underperformance against the benchmark over the last 3 years

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 10,015 Million (Small Cap)

stock-summary
P/E

33.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.34%

stock-summary
Debt Equity

0.29

stock-summary
Return on Equity

4.20%

stock-summary
Price to Book

1.33

Revenue and Profits:
Net Sales:
720 Million
(Quarterly Results - Jun 2025)
Net Profit:
55 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
19.66%
0%
19.66%
6 Months
10.98%
0%
10.98%
1 Year
-11.69%
0%
-11.69%
2 Years
11.76%
0%
11.76%
3 Years
-26.34%
0%
-26.34%
4 Years
-44.01%
0%
-44.01%
5 Years
-27.67%
0%
-27.67%

Revvity, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Revvity, Inc. overvalued or undervalued?

As of 31 October 2025, the valuation grade for Revvity, Inc. has moved from attractive to very expensive, indicating a shift towards overvaluation. The company appears to be overvalued, with a P/E ratio of 33, an EV to EBITDA of 15.29, and a PEG ratio of 3.05, which are all higher than the industry average. In comparison, The Cooper Cos., Inc. has a P/E of 34.28 and an EV to EBITDA of 14.70, while Align Technology, Inc. shows a more favorable P/E of 20.46 and an EV to EBITDA of 11.41. Furthermore, Revvity's stock has underperformed relative to the S&P 500, with a year-to-date return of -17.85% compared to the S&P 500's 16.30%, and a three-year return of -28.07% versus the S&P 500's 76.66%. This significant underperformance reinforces the notion that the stock is overvalued in its current state....

Read More

Is Revvity, Inc. overvalued or undervalued?

As of 31 October 2025, the valuation grade for Revvity, Inc. has moved from attractive to very expensive, indicating a significant shift in its market perception. The company appears to be overvalued based on its current metrics, including a P/E ratio of 33, a Price to Book Value of 1.42, and an EV to EBITDA ratio of 15.29. In comparison, peers such as Hologic, Inc. have a fair valuation with a P/E ratio of 21.83, while The Cooper Companies, Inc. is also considered very expensive with a P/E of 34.28. The stock has underperformed against the S&P 500 across multiple periods, with a year-to-date return of -16.70% compared to the S&P 500's 16.30%, and a three-year return of -27.07% versus 76.66% for the index. This underperformance further supports the conclusion that Revvity, Inc. is currently overvalued in the market....

Read More

Is Revvity, Inc. overvalued or undervalued?

As of 31 October 2025, the valuation grade for Revvity, Inc. has moved from attractive to very expensive, indicating a significant shift in its perceived value. The company appears overvalued based on its key financial metrics, including a P/E ratio of 33, an EV to EBITDA ratio of 15.29, and a PEG ratio of 3.05. In comparison, peers such as Hologic, Inc. and Align Technology, Inc. have more favorable valuations with P/E ratios of 21.83 and 20.46, respectively, suggesting that Revvity's stock is priced at a premium relative to its industry counterparts. Additionally, Revvity has underperformed against the S&P 500, with a year-to-date return of -16.15% compared to the index's positive return of 16.30%. This underperformance, alongside its elevated valuation ratios, reinforces the conclusion that Revvity, Inc. is currently overvalued....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-1.23%
EBIT Growth (5y)
-2.67%
EBIT to Interest (avg)
10.80
Debt to EBITDA (avg)
2.07
Net Debt to Equity (avg)
0.27
Sales to Capital Employed (avg)
0.25
Tax Ratio
11.35%
Dividend Payout Ratio
11.63%
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
10.24%
ROE (avg)
10.51%
Valuation key factors
Factor
Value
P/E Ratio
33
Industry P/E
Price to Book Value
1.42
EV to EBIT
30.33
EV to EBITDA
15.29
EV to Capital Employed
1.33
EV to Sales
4.65
PEG Ratio
3.05
Dividend Yield
0.32%
ROCE (Latest)
4.39%
ROE (Latest)
4.30%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 103 Schemes (57.41%)

Foreign Institutions

Held by 281 Foreign Institutions (24.63%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 8.35% vs -8.86% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 32.37% vs -52.83% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "720.30",
          "val2": "664.80",
          "chgp": "8.35%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "207.60",
          "val2": "185.40",
          "chgp": "11.97%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "22.90",
          "val2": "23.00",
          "chgp": "-0.43%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-16.00",
          "val2": "-12.70",
          "chgp": "-25.98%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "55.20",
          "val2": "41.70",
          "chgp": "32.37%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "145.50%",
          "val2": "132.30%",
          "chgp": "1.32%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.16% vs -16.95% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 57.72% vs -64.99% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,755.00",
          "val2": "2,750.60",
          "chgp": "0.16%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "838.40",
          "val2": "831.30",
          "chgp": "0.85%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "96.30",
          "val2": "98.80",
          "chgp": "-2.53%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-55.80",
          "val2": "-132.90",
          "chgp": "58.01%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "283.10",
          "val2": "179.50",
          "chgp": "57.72%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "149.00%",
          "val2": "145.20%",
          "chgp": "0.38%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
720.30
664.80
8.35%
Operating Profit (PBDIT) excl Other Income
207.60
185.40
11.97%
Interest
22.90
23.00
-0.43%
Exceptional Items
-16.00
-12.70
-25.98%
Consolidate Net Profit
55.20
41.70
32.37%
Operating Profit Margin (Excl OI)
145.50%
132.30%
1.32%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 8.35% vs -8.86% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 32.37% vs -52.83% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
2,755.00
2,750.60
0.16%
Operating Profit (PBDIT) excl Other Income
838.40
831.30
0.85%
Interest
96.30
98.80
-2.53%
Exceptional Items
-55.80
-132.90
58.01%
Consolidate Net Profit
283.10
179.50
57.72%
Operating Profit Margin (Excl OI)
149.00%
145.20%
0.38%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 0.16% vs -16.95% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 57.72% vs -64.99% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Revvity, Inc. stock-summary
stock-summary
Revvity, Inc.
Pharmaceuticals & Biotechnology
PerkinElmer Inc. is a provider of products, services and solutions for the diagnostics, life sciences and applied markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. Its Discovery & Analytical Solutions segment serves the life sciences and applied markets. Through the Diagnostics Segment, it offers instruments, reagents, assay platforms, and software to hospitals, medical labs, clinicians, and medical research professionals. It provides early detection for genetic disorders from pregnancy to early childhood, and infectious disease testing for the diagnostics market. It offers its product under various brands, BACS-on-Beads, BIOCHIPs, Bioo Scientific, BoBs, chemagic, FragilEase, Genoglyphix, GSP, PG-Seq, PG-Find, Protein Clear, ProteinEXact and QSight, Glutomatic, Honigs Regression, HyperDSC, Inframatic, LAMBDA, NexION, NEN, OneSource, Opera Phenix, Operetta CLS and OsteoSense.
Company Coordinates stock-summary
Company Details
155 Federal St Ste 700 , BOSTON MA : 02110-1727
stock-summary
Tel: 1 781 6635776
stock-summary
http://www.perkinelmer.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."